Efficasy of combination therapy PEG-IFN-alpha-2b and Ribavirin for patients with Serogroup1 and high titer HCV.

Not Applicable

• Conditions: Hepatitis C

• Registration Number: JPRN-C000000197
• Lead Sponsor: Osaka university graduate school of medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-12-31
• Study Completion: 2016-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Not provided

Exclusion Criteria

Pregnant or lactating women and women who may be pregnant Female patients or male patients with partners who may become pregnant who cannot practice contraception during treatment and 6 months after end of treatment Male patients with pregnant partners who cannot comply with condom use during treatment and 6 months after end of treatment History of hypersensitivity to ribavirin or other nucleoside analogs Inadequately controlled cardiac disease Hemoglobinopathy Chronic renal failure or renal function disorder with creatinine clearance of 50 ml/min or less With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. Serious hepatic function disorder Autoimmune hepatitis History of hypersensitivity to PEG-IFN alfa-2b or other interferons History of hypersensitivity to biological products such as vaccine Patients receiving shosaikoto Judged by investigator to be not appropriate for inclusion in study

Study & Design

• Study Type: Interventional
• Study Design: Not specified